Anti-C1q Autoantibodies, Novel Tests, and Clinical Consequences

Although anti-C1q autoantibodies have been described more than four decades ago a constant stream of papers describing clinical associations or functional consequences highlights that anti-C1q antibodies are still hot and happening. By far the largest set of studies focus on anti-C1q antibodies is s...

Full description

Bibliographic Details
Main Authors:	Mahler, Michael, van Schaarenburg, Rosanne A., Trouw, Leendert A.
Format:	Online
Language:	English
Published:	Frontiers Media S.A. 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653116/

id	pubmed-3653116
recordtype	oai_dc
spelling	pubmed-36531162013-05-28 Anti-C1q Autoantibodies, Novel Tests, and Clinical Consequences Mahler, Michael van Schaarenburg, Rosanne A. Trouw, Leendert A. Immunology Although anti-C1q autoantibodies have been described more than four decades ago a constant stream of papers describing clinical associations or functional consequences highlights that anti-C1q antibodies are still hot and happening. By far the largest set of studies focus on anti-C1q antibodies is systemic lupus erythematosus (SLE). In SLE anti-C1q antibodies associate with involvement of lupus nephritis in such a way that in the absence of anti-C1q antibodies it is unlikely that a flare in nephritis will occur. Anti-C1q antibodies occur in several autoimmune conditions but also in healthy individuals. Although considerable progress has been made in the understanding of how anti-C1q antibodies may contribute to tissue injury there is still a lot to learn about the processes involved in the breaking of tolerance to this protein. There has been considerable improvement in the assays employed to test for the presence of anti-C1q antibodies. Hopefully with these new and standardized assays at hand larger clinical association studies will be conducted with independent replication. Such large-scale studies will reveal the true value of clinical testing for anti-C1q autoantibodies in several clinical conditions. Frontiers Media S.A. 2013-05-14 /pmc/articles/PMC3653116/ /pubmed/23717311 http://dx.doi.org/10.3389/fimmu.2013.00117 Text en Copyright © 2013 Mahler, van Schaarenburg and Trouw. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Mahler, Michael van Schaarenburg, Rosanne A. Trouw, Leendert A.
spellingShingle	Mahler, Michael van Schaarenburg, Rosanne A. Trouw, Leendert A. Anti-C1q Autoantibodies, Novel Tests, and Clinical Consequences
author_facet	Mahler, Michael van Schaarenburg, Rosanne A. Trouw, Leendert A.
author_sort	Mahler, Michael
title	Anti-C1q Autoantibodies, Novel Tests, and Clinical Consequences
title_short	Anti-C1q Autoantibodies, Novel Tests, and Clinical Consequences
title_full	Anti-C1q Autoantibodies, Novel Tests, and Clinical Consequences
title_fullStr	Anti-C1q Autoantibodies, Novel Tests, and Clinical Consequences
title_full_unstemmed	Anti-C1q Autoantibodies, Novel Tests, and Clinical Consequences
title_sort	anti-c1q autoantibodies, novel tests, and clinical consequences
description	Although anti-C1q autoantibodies have been described more than four decades ago a constant stream of papers describing clinical associations or functional consequences highlights that anti-C1q antibodies are still hot and happening. By far the largest set of studies focus on anti-C1q antibodies is systemic lupus erythematosus (SLE). In SLE anti-C1q antibodies associate with involvement of lupus nephritis in such a way that in the absence of anti-C1q antibodies it is unlikely that a flare in nephritis will occur. Anti-C1q antibodies occur in several autoimmune conditions but also in healthy individuals. Although considerable progress has been made in the understanding of how anti-C1q antibodies may contribute to tissue injury there is still a lot to learn about the processes involved in the breaking of tolerance to this protein. There has been considerable improvement in the assays employed to test for the presence of anti-C1q antibodies. Hopefully with these new and standardized assays at hand larger clinical association studies will be conducted with independent replication. Such large-scale studies will reveal the true value of clinical testing for anti-C1q autoantibodies in several clinical conditions.
publisher	Frontiers Media S.A.
publishDate	2013
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653116/
_version_	1611977495643422720

Anti-C1q Autoantibodies, Novel Tests, and Clinical Consequences

Similar Items